Lasting longer at what?
A peptide lasts minutes, hours or days. Fine, but what lasts? The compound in the blood, a hormone response and a change in someone's health are different things. It's easy to slide from one to another without noticing.
Take CJC-1295. A small study measured blood levels and hormone changes in healthy adults. It used the long-acting DAC form, which has an added part that helps it stay in the blood. It didn't establish better sleep or faster recovery.
That's the question I bring to each page here: what did the researchers actually watch? If they measured a hormone, I call it a hormone result. An exciting explanation can't turn it into a better night's sleep.
Pick a reading
CJC-1295 has two forms that often get treated as one. The finding about days in the blood belongs to DAC. The form without DAC can’t borrow that number just because the names look alike.
Ipamorelin has a short blood study and a bowel-surgery trial. One looked at a hormone response. The other asked whether people could eat sooner. Those questions led to very different kinds of answers.
Semaglutide has longer studies to read, including weight changes during treatment and after it stopped. The follow-up is worth keeping beside the first result.
Tesamorelin leaves the blood quickly, while its trials watched deep abdominal fat over months. The approved medicine targets excess fat in the abdomen in adults who have HIV-related lipodystrophy, a change in how body fat is distributed.
Half-life isn't the whole story
Half-life is the time for a drug's concentration in blood to fall by half. It doesn't mean the drug has vanished. It doesn't tell us when every effect ends, either.
The tesamorelin label puts its half-life at about 11 minutes in healthy people. That can sit quite comfortably beside months of follow-up. The two clocks are watching different things.
The comparison page puts those meanings side by side. There’s no winner’s podium. I’d rather leave you with a useful question than a ranking the evidence can’t support.